Teva Sues Perrigo Over ProAir Generic Plans

Law360, New York (August 19, 2013, 2:50 PM EDT) -- Teva Pharmaceutical Industries Ltd. on Friday sued rival Perrigo Co. in Delaware federal court, alleging a planned generic version of asthma treatment ProAir HFA infringes several patents covering the drug and its dispenser.

According to the Israeli drugmaker, Allegan, Mich.-based Perrigo's planned generic albuterol sulfate aerosol inhaler, designed with drug development services company Catalent Pharma Solutions LLC, infringes on four patents licensed by Teva for ProAir: U.S. Patent Numbers 7,105,152; 7,566,445; 6,446,627; and 8,132,712.

"Upon information and belief, Perrigo and Catalent have knowingly and willfully infringed...
To view the full article, register now.